Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14073898 | 0.91 | CYP3A4 (0.59) | KMT2AALDH1A1MAPTPOLBTRPV1 | |
| SCHEMBL14073568 | 0.84 | KMT2A (0.67) | KMT2AALDH1A1MAPTPOLBTRPV1 | |
| SCHEMBL14073662 | 0.82 | KMT2A (0.56) | KMT2AALDH1A1MAPTPOLBTRPV1 | |
| SCHEMBL14073638 | 0.82 | KMT2A (0.61) | KMT2AALDH1A1MAPTPOLBTRPV1 | |
| SCHEMBL14073654 | 0.82 | KMT2A (0.58) | KMT2AALDH1A1MAPTPOLBTRPV1 | |
| SCHEMBL14073375 | 0.81 | TSHR (0.60) | KMT2AALDH1A1MAPTGAA | |
| SCHEMBL8192718 | 0.80 | ALDH1A1 (0.77) | KMT2AALDH1A1MAPTPOLBTRPV1 | |
| SCHEMBL14073594 | 0.80 | CYP2C9 (0.69) | KMT2AALDH1A1MAPTPOLBTRPV1 | |
| SCHEMBL14073572 | 0.79 | KMT2A (0.63) | KMT2AALDH1A1MAPTPOLBTRPV1 | |
| SCHEMBL14073577 | 0.78 | MAPT (0.64) | KMT2AALDH1A1MAPTPOLBTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | MMP12, MMP13, MMP25 | KMT2A 2900/4885ALDH1A1 714/4885MAPT 3986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.